Emerging personalized approaches for the management of advanced urothelial carcinoma

Che Kai Tsao, Benjamin A. Gartrell, William K. Oh, Matthew D. Galsky

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)1537-1543
Number of pages7
JournalExpert Review of Anticancer Therapy
Volume12
Issue number12
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

    Fingerprint

Keywords

  • biomarker
  • bladder cancer
  • chemotherapy
  • neoadjuvant therapy
  • personalized medicine
  • urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this